Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
By J. Killestein. New England Journal of Medicine, 2002
688 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/d54eabeb1b00f694b59e3156b18c31bfee77d549
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
In Surgery
Citations in the corpus
- A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes (2005, background): “We previously reported that the mAb prevented the loss of insulin production over the 1st year after diagnosis of type 1 diabetes in the initial one-half of the study entrants (21).”
- Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. (2005, background): “Autoreactive T-cells that recognize these and other islet autoantigens have been identified and are thought to play a direct role in type 1 diabetes immunopathogenesis (3–6), a proposal supported by studies showing that administration of therapeutic agents that inhibit T-cell function delays disease”
- Normalization of Obesity-Associated Insulin Resistance through Immunotherapy: CD4+ T Cells Control Glucose Homeostasis (2009, background): “CD3-specific antibody is a potent, clinically used immunosuppressant, and a possible therapeutic in type 1 diabete”
- Type 1 diabetes: etiology, immunology, and therapeutic strategies. (2011, background): “Three years after treatment, the patients continued to have better preservation of C-peptide levels and a lower use of insulin compared with control groups (185, 186).”
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003, background): “(9) on the efficacy of nonmitogenic antiCD3 mAb in humans with type 1diabetes was a direct translation of the original studies reported in the NOD mouse almost a decade earlier (10).”
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells (2006, background): “In this regard, there are currently several settings, including the treatment of humans with T1D with anti-CD3 that induces T cells with a regulatory phenotype (11, 31, 43, 44).”